Medicare Enrolled
Dr. Minal Barve, M.D.
Medical Oncology · Dallas, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Barve from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Barve?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Barve
Dr. Minal Barve is a medical oncology specialist in Dallas, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Barve performed 57,484 Medicare services across 2,795 unique beneficiaries.
Between the years covered by Open Payments, Dr. Barve received a total of $23,971 from 35 pharmaceutical and/or device companies across 131 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Barve is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 18% volume in TX
$23,971 industry payments
Medicare Practice Summary
Medicare Utilization ↗57,484
Medicare services
Top 18% in TX for medical oncology
2,795
Unique beneficiaries
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,025 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 11,400 | $43 | $136 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
9,300 | $0 | $5 |
| Filgrastim injection (Zarxio) for white blood cells An injection of the biosimilar medication filgrastim-sndz (Zarxio) with a dosage of 1 microgram. |
7,320 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
5,855 | $2 | $20 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
5,600 | $0 | $2 |
| Paclitaxel chemotherapy injection | 4,602 | $0 | $8 |
| Immune globulin infusion (Octagam) This procedure involves the administration of immune globulin medication directly into a vein. It is provided in a non-lyophilized liquid form. |
2,300 | $33 | $232 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,108 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 1,020 | $18 | $65 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
838 | $8 | $20 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
761 | $10 | $64 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
749 | $8 | $36 |
| Injection, granisetron hydrochloride, 100 mcg | 730 | $0 | $24 |
| Anti-nausea injection (Aloxi/palonosetron) | 720 | $1 | $114 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
624 | $6 | $31 |
| Magnesium level test A blood test to measure the amount of magnesium in your body. This helps check for magnesium deficiency or excess. |
569 | $7 | $29 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
342 | $91 | $368 |
| Immunoglobulin level test A blood test that measures the level of gammaglobulins, which are immune system proteins. |
273 | $9 | $56 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
264 | $136 | $496 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
250 | $23 | $157 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
245 | $102 | $707 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
213 | $2 | $300 |
| Immunoglobulin light chain measurement A blood test that measures the levels of immunoglobulin light chains, which are proteins produced by plasma cells. |
176 | $17 | $60 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
173 | $13 | $60 |
| Iron level test | 165 | $6 | $27 |
| Iron binding capacity test A blood test that measures the amount of iron in the blood and the blood's ability to bind and transport iron. |
165 | $9 | $35 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
160 | $7 | $431 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 125 | $3 | $373 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
113 | $11 | $96 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
100 | $50 | $313 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
92 | $61 | $250 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
86 | $12 | $108 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
84 | $2 | $19 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
82 | $4 | $22 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
82 | $6 | $34 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
75 | $19 | $99 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
75 | $1 | $7 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
66 | $51 | $344 |
| Uric acid level test A blood test that measures the level of uric acid in your body. Uric acid is a waste product formed when the body breaks down purines. |
61 | $4 | $25 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
59 | $23 | $161 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
54 | $58 | $211 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
53 | $16 | $100 |
| Urinalysis with microscopic exam A urine test performed manually that includes examining the sample under a microscope to check for abnormalities. |
42 | $3 | $28 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
40 | $1 | $8 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
36 | $1 | $19 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
34 | $10 | $75 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
28 | $25 | $256 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
28 | $26 | $145 |
| PSA test (prostate cancer screening) | 25 | $18 | $94 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 24 | $91 | $657 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
23 | $1,183 | $4,802 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
20 | $30 | $247 |
| Beta-2 microglobulin level test A blood test that measures the level of beta-2 microglobulin, a protein produced by cells in the body. |
15 | $16 | $96 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
15 | $67 | $264 |
| New patient office visit, complex (60-74 min) | 14 | $159 | $709 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
11 | $129 | $565 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
5.5% high complexity
84.6% medium
9.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$23,971
Total received (2018-2024)
Avg $3,424/year across 7 years
Top 29% in TX for medical oncology
35
Companies
131
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$18,473 (77.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,748 (15.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,750 (7.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$5,179
2023
$7,191
2022
$3,032
2021
$12
2020
$2,026
2019
$5,332
2018
$1,198
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Boehringer Ingelheim International GmbH
$13,846
F. Hoffmann-La Roche AG
$4,258
Astellas Pharma Global Development
$1,750
Novartis Pharmaceuticals Corporation
$436
Boehringer Ingelheim Pharmaceuticals, Inc.
$396
Janssen Biotech, Inc.
$387
Karyopharm Therapeutics Inc.
$385
TESARO, Inc.
$314
BeiGene USA, Inc.
$291
Janssen Scientific Affairs, LLC
$262
Pharmacyclics LLC, An AbbVie Company
$257
AstraZeneca Pharmaceuticals LP
$207
Celgene Corporation
$177
Novocure Inc.
$157
Kite Pharma, Inc.
$128
Merck Sharp & Dohme Corporation
$108
E.R. Squibb & Sons, L.L.C.
$82
Theratechnologies Inc.
$65
Menarini Silicon Biosystems, Inc.
$56
Ipsen Biopharmaceuticals, Inc
$52
PFIZER INC.
$47
ABBVIE INC.
$46
GlaxoSmithKline, LLC.
$44
Merck Sharp & Dohme LLC
$41
Tempus AI, Inc
$29
MorphoSys, US Inc.
$23
Takeda Pharmaceuticals U.S.A., Inc.
$17
Incyte Corporation
$16
Dendreon Pharmaceuticals LLC
$16
Genentech USA, Inc.
$15
Clovis Oncology, Inc.
$15
Foundation Medicine, Inc.
$14
Gilead Sciences, Inc.
$12
Teva Pharmaceuticals USA, Inc.
$11
Seattle Genetics, Inc.
$11
Top 3 companies account for 82.8% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · Alecensa · BENDEKA · BOSULIF · BRUKINSA · CALQUENCE · Cellsearch · DARZALEX · EGRIFTA · ENHERTU · ERLEADA · Erleada · FOUNDATIONONE · GILOTRIF · GLEEVEC · IBRANCE · IMBRUVICA · IMFINZI · Imbruvica · JEMPERLI · KEYTRUDA · KISQALI · LYNPARZA · MONJUVI · Non-Covered Product · OJJAARA · OPDIVO · Oncology · PADCEV · PIQRAY · PROVENGE · Pomalyst · RYBREVANT · Revlimid · Rubraca · SANDOSTATIN · SOMATULINE DEPOT · TABRECTA · TASIGNA · VENCLEXTA · XPOVIO · XTANDI · Yescarta · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (77%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware.
Equivalent to $42 per 100 Medicare services performed
Geographic Context
Medical oncologists within 10 mi
91
Per 100K population
3.5
County median income
$74,149
Nearest hospital
TEXAS HEALTH PRESBYTERIAN HOSPITAL DALLAS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Barve is a mixed practice specialist, with above-average Medicare volume (top 18% in TX), with speaking/promotional industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Barve experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Barve performed 11,400 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Barve receive payments from pharmaceutical companies?
Yes. Dr. Barve received a total of $23,971 from 35 companies across 131 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Barve's costs compare to other medical oncologists in Dallas?
Dr. Barve's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Barve) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Dallas
Browse medical oncologists in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
Boehringer Ingelheim International GmbH Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim International GmbH.
By company
F. Hoffmann-La Roche AG Payments to Doctors
See all physicians who received payments from F. Hoffmann-La Roche AG.
By company
Astellas Pharma Global Development Payments to Doctors
See all physicians who received payments from Astellas Pharma Global Development.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology